Drug Type Monoclonal antibody |
Synonyms ZB 002, ZB002 |
Target |
Action inhibitors |
Mechanism TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Rheumatoid Arthritis | Phase 1 | Australia | 08 Dec 2022 | |
Rheumatoid Arthritis | Phase 1 | New Zealand | 08 Dec 2022 | |
Autoimmune Diseases | Preclinical | United States | 30 Jan 2022 | |
Autoimmune Diseases | Preclinical | United States | 30 Jan 2022 |
Phase 1 | - | 8 | lgljszbgye(fhwjdisixo) = No safety signals were identified by the SRC, with adverse events consistent with expectations in a HV population. ahmtkjkghc (zgeenwcrvh ) View more | Positive | 14 Jun 2024 | ||
Placebo |